A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2017
At a glance
- Drugs MK 7684 (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms MK-7684-001
- Sponsors Merck Sharp & Dohme
- 17 Aug 2017 Planned number of patients changed from 336 to 240.
- 11 May 2017 Planned number of patients changed from 120 to 336.
- 11 May 2017 Planned primary completion date changed from 1 Mar 2018 to 23 Mar 2020.